ES2162078T3 - Compuestos terapeuticos. - Google Patents

Compuestos terapeuticos.

Info

Publication number
ES2162078T3
ES2162078T3 ES96920967T ES96920967T ES2162078T3 ES 2162078 T3 ES2162078 T3 ES 2162078T3 ES 96920967 T ES96920967 T ES 96920967T ES 96920967 T ES96920967 T ES 96920967T ES 2162078 T3 ES2162078 T3 ES 2162078T3
Authority
ES
Spain
Prior art keywords
hydrogen
oac
compounds
therapeutic compounds
nhac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96920967T
Other languages
English (en)
Inventor
Stephen Martin Courtney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9512868.2A external-priority patent/GB9512868D0/en
Priority claimed from GBGB9608372.0A external-priority patent/GB9608372D0/en
Priority claimed from GBGB9608547.7A external-priority patent/GB9608547D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Application granted granted Critical
Publication of ES2162078T3 publication Critical patent/ES2162078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Abstract

SE REVELAN COMPUESTOS DE FORMULA (I), EN DONDE R ES HALOGENO; Y ES HIDROGENO, NH 2 , SH U OH; X ES (II), EN DONDE R 1 O R 2 SON UN ENLACE, SIENDO EL OTRO UN HIDROGENO; R 3 O R 4 SON UN HIDROGENO, SIENDO EL OTRO HIDROGENO, OH, OAC O NHAC, R 5 ES OH U OAC; R 7 O R 8 SON UN HIDROGENO, SIENDO EL OTRO OH U OAC; R9 ES HIDROGENO, CH SUB,2 OH O CH 2 OAC; CON LA ESTIPULACION DE QUE CUANDO R 4 ES OH, OAC O NHAC, ENTONCES R 8 ES HIDROGENO; Y ENANTIOMEROS DE TALES COMPUESTOS. TAMBIEN SE PROPORCIONAN FORMULAS FARMACEUTICAS QUE COMPRENDEN TALES COMPUESTOS, SU USO EN EL TRATAMIENTO DE DIVERSAS ENFERMEDADES, Y METODOS DE TRATAMIENTO EN LOS QUE SE EMPLEAN ESOS COMPUESTOS.
ES96920967T 1995-06-23 1996-06-24 Compuestos terapeuticos. Expired - Lifetime ES2162078T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9512868.2A GB9512868D0 (en) 1995-06-23 1995-06-23 Therapeutic compounds
GBGB9608372.0A GB9608372D0 (en) 1996-04-23 1996-04-23 Therapeutic compounds
GBGB9608547.7A GB9608547D0 (en) 1996-04-25 1996-04-25 Therapeutic compounds
US1676296P 1996-05-03 1996-05-03
US1697396P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
ES2162078T3 true ES2162078T3 (es) 2001-12-16

Family

ID=27517294

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96920967T Expired - Lifetime ES2162078T3 (es) 1995-06-23 1996-06-24 Compuestos terapeuticos.

Country Status (16)

Country Link
US (1) US5945406A (es)
EP (1) EP0851866B1 (es)
JP (1) JPH11507942A (es)
KR (1) KR19990028344A (es)
CN (1) CN1196059A (es)
AT (1) ATE204878T1 (es)
AU (1) AU6234296A (es)
CA (1) CA2225247A1 (es)
DE (1) DE69614867T2 (es)
ES (1) ES2162078T3 (es)
HU (1) HUP9901438A3 (es)
ID (1) ID16479A (es)
IL (1) IL122700A0 (es)
NO (1) NO976043L (es)
PL (1) PL328266A1 (es)
WO (1) WO1997000882A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1196059A (zh) * 1995-06-23 1998-10-14 牛津糖科学(英国)有限公司 治疗化合物
DE19741738A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Linker-Nucleosid, seine Herstellung und Verwendung
DE19741715A1 (de) 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
DE19837387A1 (de) 1998-08-18 2000-02-24 Aventis Res & Tech Gmbh & Co 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung
US6344460B1 (en) * 1999-03-19 2002-02-05 Lonza Inc. Propynyl uracils
US20050143300A1 (en) * 2003-10-10 2005-06-30 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
ES2628180T3 (es) 2008-07-11 2017-08-02 Board Of Regents, The University Of Texas System Nuevos acetatos de 2-desoxi monosacáridos con actividad anticancerosa
ES2897699T3 (es) 2013-04-05 2022-03-02 Univ Texas Esteres de 2-desoxi-monosacáridos con actividad antiproliferativa

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354160A (en) * 1965-07-22 1967-11-21 Hoffmann La Roche Tri-lower alkyl-silyl-5-fluoropyrimidines
DK149818C (da) * 1976-10-28 1987-04-06 Sankyo Co Analogifremgangsmaade til fremstilling af 5-fluoruracil-derivater
US4248999A (en) * 1976-10-28 1981-02-03 Sankyo Company Limited 5-Fluorouracil derivatives and process for preparing thereof
JPS55153796A (en) * 1979-05-21 1980-11-29 Meiji Seika Kaisha Ltd 5-fluorouracil nucleoside and its preparation
JPS5829798A (ja) * 1981-08-15 1983-02-22 Tetsuo Suami ヌクレオシド類似体
JPS5872599A (ja) * 1981-10-27 1983-04-30 Kanto Ishi Pharma Co Ltd 複合糖質誘導体
EP0119650A3 (en) * 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics
JP2696393B2 (ja) * 1989-05-09 1998-01-14 株式会社日本抗体研究所 チミン誘導体及びこれを含有する抗ｈｉｖ剤
JPH0517494A (ja) * 1991-07-10 1993-01-26 Nippon Shoji Kk グルコサミン誘導体
ATE284894T1 (de) * 1994-10-24 2005-01-15 Genencor Int L-pyranosyl-nukleoside
CN1196059A (zh) * 1995-06-23 1998-10-14 牛津糖科学(英国)有限公司 治疗化合物
GB9626450D0 (en) * 1996-12-20 1997-02-05 Oxford Glycosciences Uk Ltd Therapeutic compounds

Also Published As

Publication number Publication date
DE69614867T2 (de) 2002-04-11
US5945406A (en) 1999-08-31
NO976043L (no) 1998-02-20
EP0851866A1 (en) 1998-07-08
CA2225247A1 (en) 1997-01-09
ATE204878T1 (de) 2001-09-15
IL122700A0 (en) 1998-12-06
HUP9901438A2 (hu) 1999-08-30
AU6234296A (en) 1997-01-22
JPH11507942A (ja) 1999-07-13
NO976043D0 (no) 1997-12-22
KR19990028344A (ko) 1999-04-15
CN1196059A (zh) 1998-10-14
ID16479A (id) 1997-10-02
HUP9901438A3 (en) 2000-07-28
MX9710529A (es) 1998-08-30
DE69614867D1 (de) 2001-10-04
PL328266A1 (en) 1999-01-18
WO1997000882A1 (en) 1997-01-09
EP0851866B1 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
DK0584136T3 (da) Bestemmelse af peptidmotiver på MHC-molekyler
ID28003A (id) Turunan-turunan adamantana
GB9514473D0 (en) Chemical compounds
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
MY132529A (en) Paroxetine hydrochloride anhydrate
ATE151764T1 (de) Neue benzopyran-derivate, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltenden zubereitungen
MX9701679A (es) Derivados de piperidina como antagonistas de la neuroquinina.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
UA41355C2 (uk) Засіб для лікування нейро-сніду
ES2158327T3 (es) Derivados de benzo(g)quinolina.
ATE203519T1 (de) Chinolinderivate als antimalariamittel
ES2162078T3 (es) Compuestos terapeuticos.
NO971903D0 (no) Krystallisering av levobupivacain og analoger derav
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
ATE113056T1 (de) Künstliche rezeptor-analoge.
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
ATE169019T1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
FI891473A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
ES2088661T3 (es) Bis-naftalimidas fuertemente solubles en agua utiles como agentes anti-cancerigenos.
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
SE9404438D0 (sv) New process
DE3268605D1 (en) 3,7a-diazacyclohepta(j,k)fluorene derivatives, their preparation and therapeutical use
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 851866

Country of ref document: ES